Molecular Imaging Market worth US$6.183 billion by 2026

The molecular imaging market is projected to grow at a CAGR of 5.68% to reach US$6.183 billion in 2026 from US$4.199 billion in 2019.

Molecular imaging, it’s a type of medical imaging which shows what's going on within the body at the molecular and cellular levels. Wherever different diagnostic imaging procedures such as x-rays, computerized tomography (CT), and ultrasound offer footage of the organic structure, molecular imaging permits physicians to visualize however the body is functioning and to live its chemical and biological processes. Molecular imaging offers distinctive insights into the organic structure that alter physicians to change patient care.

Technological advancements within the medical sector can more contribute to plugging growth. Bound factors that are dynamic in the expansion of the market embody technological advancements, increasing diagnostic applications in varied diseases, like cancer and cardiovascular diseases, government support, and a shift from standalone to hybrid modalities.

Geographically, North America dominates the worldwide molecular imaging market whereas the Asia Pacific is predicted to be the fastest-growing market within the years ahead because of rising healthcare payments in the rising economies of the region.

The advent of COVID-19 had a small decline within the world molecular imaging market

The impact on this business was primarily due to the very fact that imaging procedures were in deep trouble with preventive measures in addition throughout the amount. Some facilities opted to keep their doors open, when potential, to continue serving people who required scans for varied medical reasons, like cancer patients. Off-site imaging firms did facilitate strengthen the potential surge in patients by keeping imaging processes moving forward. This was done to assist to scale back the unfold of COVID-19 and additionally to diagnose it sooner and easier in remote locations that were coming upon nationwide. In April 2020, the U.S. Food and Drug Administration (FDA) issued directing to supply a policy to assist expand the provision and capability of medical X-ray, ultrasound and resonance imaging (MRI) systems, and image analysis software utilized to diagnose and monitor medical conditions whereas mitigating circumstances that would result in a patient, healthcare supplier exposure to COVID-19.

View a sample of the report or purchase the complete study at


  • By Device type
    • Positron Emission Tomography Scanner
    • Single Photon Emission Computed Tomography Scanner
    • Gamma Camera
    • Nuclear Magnetic Resonance Spectrometer
    • Others
  • By Application
    • Cardiovascular
    • Neurology
    • Respiratory
    • Oncology
    • Other
  • By End-user
    • Hospitals
    • Ambulatory Surgical Centres
    • Diagnostic Imaging Centres
  • By Geography
    • North America
      • USA
      • Canada
      • Mexico
    • South America
      • Brazil
      • Argentina
      • Others
    • Europe
      • Germany
      • France
      • UK
      • Others
    • Middle East & Africa
      • Saudi Arabia
      • UAE
      • Others
    • Asia Pacific
      • China
      • India
      • Japan
      • South Korea
      • Taiwan
      • Thailand
      • Indonesia
      • Others